Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 57 min ago
Peer-reviewedLicence not statedCell Research

Ursodeoxycholic acid enhances cancer radioimmunotherapy by releasing a human-biased FXR-TRIM22-STAT1 immune brake

  • Xinyan Li1
  • Peicheng Jiang1
  • Huan Yin1
  • Zhenyu Huo1
  • Xin Xu1
  • Somaira Nowsheen2
  • Khaled Aziz3
  • Sufei Zheng4
  • Nan Sun4
  • Bin Chen5
  • Zhenkun Lou6
  • Min Deng1
6 affiliations
  1. 1State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  2. 2Department of Dermatology, The Iowa Clinic, Waukee, IA USA
  3. 3Department of Radiation Oncology, Mayo Clinic, Rochester, MN USA
  4. 4Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  5. 5Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University, Hefei, Anhui China
  6. 6Department of Oncology, Mayo Clinic, Rochester, MN USA
Read full textDOICite

Related

  1. Neoadjuvant Apalutamide With or Without Abiraterone Acetate Plus Prednisone and Gonadotropin-Releasing Hormone Agonist Prior to Nerve-Sparing Radical Prostatectomy in High-Risk Prostate Cancer: Protocol for a Randomized Phase 2 Trial
    Anthony Y Zhang, Mark N Stein, Saum Ghodoussipour +1
    JMIR Research ProtocolsPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Acquired Palmoplantar Keratoderma Revealing Primary Biliary Cholangitis: Therapeutic Response to Ursodeoxycholic Acid.
    Hajar Dahmani, Ouiame El Jouari, Sabrina Oujdi +1
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  3. Telmisartan enhances anti-PD-1 efficacy in MSS colorectal cancer via modulation of PD-L1 and STAT3 signaling
    Xin Lin, Jingying Li, Wei Lin
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells
    C. Faundez Vidiella, Y. Sfragano, I. Tusa +4
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  5. Epigenetic age acceleration enhances prediction of overall survival in early-stage non-small cell lung cancer
    Isabella Gandara, Mulong Du, Yi Li +5
    iSciencePeer-reviewedCC BY 4.0Full textOncologyCell PressCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{li2026ursodeoxycholic,
  title = {{Ursodeoxycholic acid enhances cancer radioimmunotherapy by releasing a human-biased FXR-TRIM22-STAT1 immune brake}},
  author = {Xinyan Li and Peicheng Jiang and Huan Yin and Zhenyu Huo and Xin Xu and Somaira Nowsheen and Khaled Aziz and Sufei Zheng and Nan Sun and Bin Chen and Zhenkun Lou and Min Deng},
  journal = {Cell Research},
  year = {2026},
  month = sep,
  doi = {10.1038/s41422-026-01293-x},
  url = {https://doi.org/10.1038/s41422-026-01293-x},
}
RIS
TY  - JOUR
TI  - Ursodeoxycholic acid enhances cancer radioimmunotherapy by releasing a human-biased FXR-TRIM22-STAT1 immune brake
AU  - Xinyan Li
AU  - Peicheng Jiang
AU  - Huan Yin
AU  - Zhenyu Huo
AU  - Xin Xu
AU  - Somaira Nowsheen
AU  - Khaled Aziz
AU  - Sufei Zheng
AU  - Nan Sun
AU  - Bin Chen
AU  - Zhenkun Lou
AU  - Min Deng
PY  - 2026
DA  - 2026/09/30
JO  - Cell Research
DO  - 10.1038/s41422-026-01293-x
UR  - https://doi.org/10.1038/s41422-026-01293-x
SN  - 1001-0602
SN  - 1748-7838
ER  -